A Randomized, Double-blind, Placebo Controlled, Repeat Dose Phase 1b Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled GSK3923868 During Experimental Human Rhinovirus Infection in Participants With Mild Asthma
Latest Information Update: 13 Jun 2024
At a glance
- Drugs GSK 3923868 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
Most Recent Events
- 30 Nov 2022 Planned End Date changed from 28 Apr 2023 to 27 Jul 2023.
- 30 Nov 2022 Planned primary completion date changed from 28 Apr 2023 to 27 Jul 2023.
- 17 May 2022 New trial record